Journal article
High dose of plasmid IL-15 inhibits immune responses in an influenza non-human primates immunogenicity model
Virology (New York, N.Y.), v 393(1), pp 49-55
2009
PMID: 19683780
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Interleukin (IL)-15, is a cytokine that is important for the maintenance of long-lasting, high-avidity T cell response to invading pathogens and has, therefore, been used in vaccine and therapeutic platforms as an adjuvant. In addition to pure protein delivery, plasmids encoding the IL-15 gene have been utilized. However, it is critical to determine the appropriate dose to maximize the adjuvanting effects. We immunized rhesus macaques with different doses of IL-15 expressing plasmid in an influenza non-human primate immunogenicity model. We found that co-immunization of rhesus macaques with a Flu DNA-based vaccine and low doses of plasmid encoding macaque IL-15 enhanced the production of IFN-γ (0.5 mg) and the proliferation of CD4
+ and CD8
+ T cells, as well as T
CM levels in proliferating CD8
+ T cells (0.25 mg). Whereas, high doses of IL-15 (4 mg) decrease the production of IFN-γ and the proliferation of CD4
+ and CD8
+ T cells and T
CM levels in the proliferating CD4
+ and CD8
+ T cells. In addition, the data of hemagglutination inhibition (HI) antibody titer suggest that although not significantly different, there appears to be a slight increase in antibodies at lower doses of IL-15. Importantly, however, the higher doses of IL-15 decrease the antibody levels significantly. This study demonstrates the importance of optimizing DNA-based cytokine adjuvants.
Metrics
Details
- Title
- High dose of plasmid IL-15 inhibits immune responses in an influenza non-human primates immunogenicity model
- Creators
- Jiangmei Yin - Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, 505 SCL, 422 Curie Blvd. Philadelphia, PA 19104, USAAnlan Dai - Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, 505 SCL, 422 Curie Blvd. Philadelphia, PA 19104, USADominick J Laddy - Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, 505 SCL, 422 Curie Blvd. Philadelphia, PA 19104, USAJian Yan - Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, 505 SCL, 422 Curie Blvd. Philadelphia, PA 19104, USATatiana Arango - Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, 505 SCL, 422 Curie Blvd. Philadelphia, PA 19104, USAAmir S Khan - VGX Pharmaceuticals, Inc., The Woodlands, TX 77381, USAMark G Lewis - Research Section, Bioqual, Rockville, MD 20850, USAHanne Andersen - Research Section, Bioqual, Rockville, MD 20850, USAMichele A Kutzler - Drexel University College of Medicine, Philadelphia, PA 19102, USARuxandra Draghia-Akli - VGX Pharmaceuticals, Inc., The Woodlands, TX 77381, USADavid B Weiner - Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, 505 SCL, 422 Curie Blvd. Philadelphia, PA 19104, USAJean D Boyer - Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, 505 SCL, 422 Curie Blvd. Philadelphia, PA 19104, USA
- Publication Details
- Virology (New York, N.Y.), v 393(1), pp 49-55
- Publisher
- Elsevier
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Infectious Diseases (and HIV Medicine)
- Web of Science ID
- WOS:000270453600008
- Scopus ID
- 2-s2.0-70349383965
- Other Identifier
- 991014878070004721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Industry collaboration
- Domestic collaboration
- Web of Science research areas
- Virology